PatternsRadar
Sign in

AKUMSAkums Drugs and Pharmaceuticals Limited

NSEBand 10%
696.20INR-16.65 (-2.34%)Close · 20 Nov 2026
2 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹10,958 CrMarket cap
30.1P/E (TTM)
63.1%Delivery

Filings & corporate actions

11 results filed
CSV
Next results · Q3 FY27
Expected 2 Feb 2027 – 25 Feb 2027
Estimate: filed 33–56 days after quarter end, last 8 times
Dividend
₹3.00 per share · last 3 Jul 2026
2026
  • 2 NovresultsResults · Q2 FY27 · consolidated and standalone+3.8%NSE
  • 12 OctshareholdingShareholding · 30 Sept 2026-0.1%NSE
  • 8 AugresultsResults · Q1 FY27 · consolidated and standalone+4.7%NSE
  • 25 JulresultsResults · Q4 FY26 · standalone-1.7%NSE
  • 18 JulshareholdingShareholding · 30 Jun 2026+1.7%NSE
  • 3 JuldividendDividend · ₹3.00 per share-1.7%
  • 14 MayresultsResults · Q4 FY26 · consolidated and standalone-2.1%NSE
  • 7 AprshareholdingShareholding · 31 Mar 2026-0.8%NSE
  • 13 FebresultsResults · Q3 FY26 · consolidated and standalone+5.7%NSE
  • 12 JanshareholdingShareholding · 31 Dec 2025-0.1%NSE

Reaction to results · all yearsrose on day 0 in 3 of 10 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY272 Nov 2026+3.8%+4.5%—9.3×
Q1 FY278 Aug 2026+4.7%+6.7%+8.2%9.5×
Q4 FY2614 May 2026-2.1%-1.5%+17.4%1.8×
Q3 FY2613 Feb 2026+5.7%+5.1%+2.8%25.1×
Q2 FY2613 Nov 2025-3.0%-3.6%-3.3%6.1×
Q1 FY268 Aug 2025-0.1%-0.2%-2.4%3.3×
Q4 FY2526 May 2025-0.8%-3.3%-7.9%7.4×
Q3 FY256 Feb 2025-2.4%-8.9%-14.3%0.9×
Q2 FY259 Nov 2024-10.0%-27.1%-23.0%2.8×
Q1 FY2524 Aug 2024-5.0%-11.4%-9.0%—
Average-0.9%-4.0%-3.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+31.9%
Profit YoY+176.7%
Interest cost YoY+74.8%
Revenue QoQ+15.1%
Profit QoQ+12.8%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

Open712.85
Day range693.90 – 717.10
52-week range409.30 – 838.80
From 52w high-17.0%
RSI (14)37.2
ATR (14)25.77
Volume1.54L
Avg volume (20D)2.70L
Rel volume0.57×
Volatility (1Y)33.7%
Turnover₹10.8Cr
Traded value (NSE)₹10.8Cr
VWAP700.94
SMA 50 / 200757.18 / 625.49
Price band10%

Delivery percentage

Latest · 20 Nov 202663.1%
20-day avg48.1%
1-year avg51.0%
Percentile (own history)87th
Range13.6–100.0%
Sessions570

Over the last 20 sessions AKUMS settled 48.1% of its traded quantity, which is above average for an NSE equity. Its one-year average is 51.0%, so recent sessions are running 2.9 points lower than usual. The latest session ranks higher than 87% of the 570 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.43%
Dividend, trailing 12M₹3.00
Paid every year for1 yr
Shareholders67.6K · -3.8% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy333 days ago

Performance returns

1D1W1M3M6M1Y
Price-2.34%-6.05%+2.35%-7.53%+33.54%+64.08%

Valuation

Market cap₹10,958 Cr
Market cap (NSE)₹10,958 Cr
Free-float cap₹2,711 Cr
P/E (TTM)30.1
P/E (NSE)30.8
EPS (TTM)23.11
P/B3.1
Net margin (TTM)7.5%
Other income / PBT25.0%
ROE10.9%
Debt / equity0.01
Shares outstanding15.31Cr
Listed6 Aug 2024

Ownership

Promoter75.26%
Promoter Δ QoQ0.00 pp
Public22.01%
FII4.50%
DII11.08%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)1,159.61,157.91,166.61,342.4
YoY chg+14.8%+9.7%+13.9%+31.9%
Net profit (₹ Cr)67.781.3101.0114.6
YoY chg+2.1%-45.6%+56.1%+168.3%
Net margin5.8%7.0%8.7%8.5%
EPS4.335.536.537.37

Shareholding over time

By quarter

30 Sept 2026 · promoter 75.26% · public 22.01%
2 Aug 2024: promoter 75.26%30 Sept 2024: promoter 75.26%31 Dec 2024: promoter 75.26%31 Mar 2025: promoter 75.26%30 Jun 2025: promoter 75.26%30 Sept 2025: promoter 75.26%31 Dec 2025: promoter 75.26%31 Mar 2026: promoter 75.26%30 Jun 2026: promoter 75.26%30 Sept 2026: promoter 75.26%
2024-082026-09
  • Promoter
  • Public and others
Promoter
75.26%
Public
22.01%
Promoter change
0.00 pp
Filed
12 Oct 2026
FII
4.50%
DII
11.08%
Promoter pledged
0.00%

Who the public is

Mutual funds
7.58%

-2.19 pp QoQ

Insurance
0.12%

-0.25 pp QoQ

FPI
4.50%

+2.59 pp QoQ

Retail ≤ ₹2L
4.90%

-0.36 pp QoQ

HNI > ₹2L
0.31%

0.00 pp QoQ

NRI
0.27%

+0.03 pp QoQ

Bodies corporate
0.60%

+0.08 pp QoQ

Shareholders
67,618

-3.8% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain)Promoter · Other40.79%
Sandeep JainPromoter · Individual17.24%
Sanjeev JainPromoter · Individual17.23%
Franklin India Opportunites FundMutual fund3.90%
Akums Employee Benefits TrustOther2.73%
Clarus Capital IAIF2.23%
Bandhan Small Cap FundMutual fund1.13%
ICICI Prudential Healthcare FundMutual fund1.02%
Lata JainPromoter · Individual0.01%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 3 Jul 2026 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹3.00₹3.00
Ex-dateRecord dateDeclaredAdjusted
3 Jul 2026—₹3.00₹3.00

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Bulk & block deals · 22 Dec 2025

CSV
3 of 3 deals
By year
DateDealClientQuantityPriceValue
22 Dec 2025Buy · block, also bulkICICI PRUDENTIAL MUTUAL FUND72.79L428.00₹311.5Cr
22 Dec 2025Sell · block, also bulkRUBY QC INVESTMENT HOLDINGS PTE.LTD.72.79L428.00₹311.5Cr
6 Aug 2024Buy · bulkSMALLCAP WORLD FUND INC25.87L753.84₹195.0Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026

No surveillance measure applies to AKUMS.

Price band: 10% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue from operations1,019.11,033.11,010.41,055.51,024.01,017.51,159.61,157.91,166.61,342.4
Other income6.513.514.617.526.732.434.335.330.428.9
Total income1,025.71,046.61,025.01,073.11,050.81,049.91,193.91,193.21,197.01,371.3
Total expenses938.2958.7938.71,006.2955.1984.21,076.11,070.21,057.81,216.5
└ Finance costs13.011.95.14.523.123.323.723.924.825.7
└ Depreciation34.134.944.540.036.937.939.640.141.143.2
Profit before tax87.591.691.175.195.665.799.6121.2139.2154.7
Tax expense26.324.924.7(74.5)31.023.031.939.938.340.2
Net profit61.266.766.3149.664.742.767.781.3101.0114.6
EPS4.214.374.269.644.152.664.335.536.537.37
Net margin6.01%6.45%6.56%14.17%6.32%4.20%5.84%7.03%8.66%8.53%
PBT margin8.58%8.87%9.01%7.12%9.34%6.45%8.59%10.47%11.93%11.53%
Tax rate30.03%27.23%27.17%-99.11%32.37%34.99%32.03%32.89%27.48%25.96%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 2 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 H1 FY25FY25H1 FY26FY26H1 FY27
Total assets4,270.44,113.45,159.35,447.05,831.6
Current assets2,623.62,274.63,293.53,559.93,825.9
└ Cash & equivalents482.0101.2229.1386.0183.6
└ Other bank balances313.0475.31,425.31,294.61,425.5
└ Current investments0.00.00.00.070.9
└ Trade receivables949.3770.3746.2796.6859.5
└ Inventories659.6680.9648.4755.7903.5
Total equity2,847.03,063.63,168.43,331.13,523.3
└ Attributable to owners2,833.53,047.03,148.73,313.33,502.9
└ Non-controlling interest13.516.619.717.820.4
└ Share capital30.630.630.630.630.6
Borrowings459.213.79.873.036.2
└ Current410.013.79.873.036.2
└ Non-current49.20.00.00.00.0
Trade payables606.9642.8610.1602.2764.2
Current liabilities1,232.9893.7832.91,094.81,265.6
Total liabilities1,423.41,049.81,990.92,115.82,308.3
Net debt(335.8)(562.8)(1,644.6)(1,607.6)(1,643.8)
Debt / equity0.160.000.000.020.01
Current ratio2.132.553.953.253.02

Cash flow, year to date

 H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow70.8465.21,152.21,181.2255.7
└ Capex(150.4)(272.3)(112.0)(230.5)(154.2)
Free cash flow(79.5)192.91,040.2950.7101.5
Investing cash flow(283.7)(547.8)(1,006.5)(930.3)(354.1)
Financing cash flow583.872.8(17.8)33.9(104.0)
└ Dividends paid0.00.00.00.0(45.9)
└ Buybacks0.00.00.00.00.0
Net change in cash370.9(9.9)127.9284.8(202.4)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

AKUMS at a glance

  • AKUMS closed at ₹696.2 on 20 Nov 2026, -2.34% on the day, +64.1% over one year, 17.0% below its 52-week high of ₹838.8.
  • Delivery was 63.1% of traded quantity on 20 Nov 2026, the 87th percentile of its own 570 sessions with a reading (20-session average 48.1%, 1-year average 51.0%).
  • Market capitalisation is ₹10,958 crore at a trailing P/E of 30.1 (trailing EPS ₹23.11).
  • Q2 FY27 results (consolidated, filed 2 Nov 2026): revenue ₹1,342 crore (+31.9% year on year), net profit ₹115 crore (+168.3%); the price moved +3.8% on the first session after.
  • Promoters held 75.26% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 2 Feb 2027 and 25 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE09XN01023
SeriesEQ
Listed6 Aug 2024
IPO price679.00 · band Rs.646 to Rs.679
IPO listing6 Aug 2024
NSE market cap · 17 Nov 2026₹11,279 Cr
Free-float market cap (NSE)₹2,483 Cr
Shares outstanding (NSE)15.74Cr
History from6 Aug 2024
Sessions570
Turnover rank#730

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.